The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
“‘ Jeez its dose dependant! At the dose required for Covid treatment there are no side affects but ramp that up 10 fold and there are! The same with all medication!!!!!!!!!!!!!!!
Get a grip!!!!!!!!!!“‘
If the drug could monitor and adjust to your glucose levels then, sure it’s fine. But when it is as erratic as in a diabetic, the dosage cannot be determined and even a smaller dose than prescribed could potentially have disastrous results.
I’m not going to lecture on how diabetes works but as someone who is very close to it, this is scary.
Don’t need to read any RNS from someone to tell me about something affecting our everyday life to be fair.
Type 1 or 2 diabetics being send home by their GP with pack of these pills to severely hypo in their own home to treat COVID
isn’t an ideal solution.
Wish I could edit posts - but if someone were to take an overdose of a few of these then it could potentially be deadly.
And that’s not restricted to diabetics either but anyone who’s blood glucose would drop like this.
Insulin can kill people, and so could this if it drops blood glucose to under 1 mmol.
I’m really staring to see why this is bringing no news forward, because this stuff is potentially lethal.
This is most worrying to be fair.
“‘In addition to the severe hypoglycaemia observed at higher doses, both Wallerian type nerve degeneration and skeletal muscle fibre degeneration were observed. “‘
Severe hypoglycaemia, this is what could comatose or kill a diabetic.
I’ve read it - and having a type 1 diabetic partner, this isn’t something we’d be using to be fair.
If anything it’ll worsen any hypoglycaemia and adjustments of the intake of injected insulin would be necessary to prevent
severe hypoglycaemia - which in itself is damaging to diabetics.
“‘’ Safety and tolerability
Single-dose and multiple-dose studies with AZD1656 of up to 180 mg and 150 mg BID respectively, were conducted for 8 days in healthy volunteers, and in diabetic patients either alone or in combination with other blood glucose control agents at 200 mg daily for up to 6-months duration. In both healthy volunteers and diabetic patients no significant adverse clinical effects other than glucose lowering were noted.
Preclinical studies of up to 12-month duration have been performed. These showed a potent glucose lowering effect in healthy animals. In addition to the severe hypoglycaemia observed at higher doses, both Wallerian type nerve degeneration and skeletal muscle fibre degeneration were observed. Additional changes, also considered secondary to hypoglycaemia, were seen in the liver including the loss of hepatocellular glycogen.
”””
“” Dear VELA Board, What are you doing with the £2Mill cash you are sitting on?””
I’ve said before, I fear this is being retained for payment of the salaries for our underperforming board.
As for AZD1656 - would it be possible that perhaps the results weren’t good enough to be considered any
real competition for Merck’s tablet and the other one that’s brought into use now?
I fully understand the diabetic angle on this, but if you have a tablet that is suitable for everyone, this then includes the diabetic group too and there’s no real need to be prescribing additional tablets if you have one that works purely on the
COVID side of things and gets folk well and out of hospital. There may be a use for it within treatment of diabetics who are hospitalised but if it was as effective as we hoped then surely by now it would have been at least confirmed to be so, regardless of whatever commercialisation talks are going on.
“” Dear VELA Board, What are you doing with the £2Mill cash you are sitting on?””
I’ve said before, I fear this is being retained for payment of the salaries for our underperforming board.
As for AZD1656 - would it be possible that perhaps the results weren’t good enough to be considered any
real competition for Merck’s tablet and the other one that’s brought into use now?
I fully understand the diabetic angle on this, but if you have a tablet that is suitable for everyone, this then includes the diabetic group too and there’s no real need to be prescribing additional tablets if you have one that works purely on the
COVID side of things and gets folk well and out of hospital. There may be a use for it within treatment of diabetics who are hospitalised but if it was as effective as we hoped then surely by now it would have been at least confirmed to be so, regardless of whatever commercialisation talks are going on.
Anyone ever tried contacting him or anyone else in the company?
I did manage to get hold of an SGSC director once, who wasn’t allowed to say anything, but
that was due to instructions from elsewhere, which could be interpreted in many ways.
Wonder if anyone is living near the VELA offices and wouldn’t mind driving past to see if there’s any signs of life and an operational looking company there or only a pile of double glazing leaflets and local takeaway menus behind the front door.
Dissatisfied, disappointed and annoyed at this board of vela.
Money in the bank to pay for a few years wages, they’re treating this as a pension fund with a guaranteed payout which we can’t do nothing about. I’ve been reducing my position down at a loss to recoup in other shares. The lack of any communication, as far I can tell ignoring of shareholder emails and no RNS’ S or any form of social media updates speak volumes if you think about it. And now with Merck being approved in the first country in the world, ours of course, it’s not looking likely that this azd1656 will ever get off the ground.
I’m invested in another company that do LFT’s, they’ve got a British product that’s 100% effective, British made, only needs a saliva sample and blows any pcr tests out of the water. What does the government do? Buys Chinese tests…
I’m sorry guys, I really had high hopes for Vela but the board and SGSC are not interested in AZD1656 as it’s not as effective
as hoped and won’t see any deal or usage anytime soon. If it was as we hoped it was, it’d have been in every hospital by now.
Commercialisation doesn’t take this long for a product that is proven to save lives… it’s fast tracked and out in a few weeks.
Look at the vaccines, they take a decade to get into usage normally, yet numerous were distributed and put in arms around the world within a year. Everyone in the world knows at least 1 diabetic who is at risk of dying of COVID in a hospital, so if this worked it’d have been out on the wards saving lives.
I’m keeping a small stack of vela just incase any of the other investments come good, but to be honest our mighty leader JN can’t even be bothered talking to us, let alone spend any free equity on any new projects that may see our position as long suffering shareholders improve with a new investment. I mean why would he, we drop £175 a year in wages to these guys. For doing nothing. Why would they bother if they’re covered for the next decade without lifting a finger,
DYOR and think about it. I did and it cost me money but I gained knowledge atleast.
GLA and hope your losses aren’t too great.